

Surgaflex™ PainGuard™

SAM™ Antimicrobial Technology with Lidocaine

Managing your **PAIN POINTS** just got easier



Protecting
wounds from
infection risk



Initiating
acute pain relief



Simplifying
topical analgesic
dosing and application



Reducing
pain-related
discharge delays

Experience the **POWER** of PainGuard™

The **first** and **only** wound care matrix to incorporate broad spectrum **antimicrobial** silver **PLUS** lidocaine to manage **both** infection risk and pain.

2 important considerations
in wound healing

managed
with just **1** Solution


How it **Works**:

- ✓ **SAM™ Technology**, a porous matrix of **bioresorbable** polymers, **conforms to micro-textures** of the wound^{1,2} and facilitates a moist and cytophillic wound-healing environment^{1,2} that allows for cells to attach, adhere, migrate and proliferate^{1†}
- ✓ The matrix contains **ionic** and **metallic silver** at a low, non-toxic level, providing at least **72 hours of sustained, 99.99% reduction in microbial burden**^{3†}
- ✓ With the added benefit of **PainGuard™**, the matrix delivers a **unit-dose, uniform release of lidocaine** comparable to a **4% lidocaine ointment**,⁴ providing accurate administration and preventing side effects from excessive dosages of uneven gels or ointments
- ✓ **>80% release of lidocaine within 30 minutes**⁴ provides immediate, **acute pain relief** across a wide range of wound types, including **surgical, burn, donor site, trauma, and chronic wounds**. It is especially **beneficial during painful excisions** and also procedures such as **dressing changes** and **debridement**.

The **IMPACT** of Infection & Pain

- ✓ It is estimated that **Surgical Site Infections (SSIs)** develop in **2-5%** of patients undergoing inpatient surgical procedures each year in the U.S.⁵
- ✓ Nearly **90% of patients** undergoing surgery **report postoperative pain**, which is often moderate to severe in intensity⁶

Infection and pain contribute to increased morbidity, delayed recovery, and higher risk of chronic issues and impaired quality of life, costing the healthcare system millions.




Address your **Pain Points** with Surgaflex™ PainGuard™

- ✓ **Relieve initial pain** and **provide antimicrobial protection BEFORE or AFTER** a procedure with a dose-controlled, **1-step solution**
- ✓ **Help improve patient discomfort** for better compliance to **accelerate healing**
- ✓ **Facilitate timely patient discharge**

Your **One-Solution Answer** for managing infection risk and pain in wounds.

Product Size (cm)	Product Size (in)	Product Number / Reference	Product Description (sterile, individually packaged)	Total (cm ²)	Total Lidocaine Quantity per Piece (mg)
2 x 3 cm	0.8 x 1.2 in	SFPG 0203	Surgaflex™ PainGuard™, 2 x 3 cm	6 cm ²	2.4 mg
4 x 6 cm	1.6 x 2.4 in	SFPG 0406	Surgaflex™ PainGuard™, 4 x 6 cm	24 cm ²	9.6 mg
4 x 10 cm	1.6 x 3.9 in	SFPG 0410	Surgaflex™ PainGuard™, 4 x 10 cm	40 cm ²	16.0 mg
4 x 20 cm	1.6 x 7.9 in	SFPG 0420	Surgaflex™ PainGuard™, 4 x 20 cm	80 cm ²	32.0 mg

Surgaflex™ PainGuard™ contains 0.4 mg/cm² lidocaine; a single dose of lidocaine should not exceed 300 mg, or 4.5 mg/kg⁷



- ✓ **Easy to open and use**
- ✓ **Needs NO refrigeration**
- ✓ **2 year shelf life**

Customer Service:

Customer Care email:
cs@Imbedbio.com
Phone:
888.472.9898
Hours:
8am - 5pm CT

REFERENCES: 1. Agarwal, A., et al. Surfaces modified with nanometer-thick silver-impregnated polymeric films that kill bacteria but support growth of mammalian cells. *Biomaterials*. 2010;31(4):680-690. 2. Study 15T_41113_02, Systemic Toxicity, Local Tissue Response, and Wound Healing Study of Microlyte Ag, Following Repeated Treatment to Full-Thickness Wounds in Rats – 28 Days. Data on file, Imbed Biosciences. 3. U.S. Food and Drug Administration. 510(k) Summary K211943: Microlyte Ag/Lidocaine. FDA. gov. Published July 2021. Accessed August 9, 2025. https://www.accessdata.fda.gov/cdrh_docs/pdf21/K211943.pdf. 4. 19-01 Report, Silver-Lidocaine Release Profiles of Microlyte Ag/Lidocaine Wound Dressing (DOC-907). Data on file, Imbed Biosciences. 5. Berrios-Torres, S., et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection. *JAMA Surg*, 152 (8), 784-791, 2017. 6. Gan, TJ, et al. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. *Curr Med Res Opin*, 30:149-160, 2014. 7. <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=0c0790ec-ef4d-4d8a-9874-8ca0b31e54d0&type=display>

† As demonstrated *in vitro*

©2025 Imbed Biosciences, Inc. All rights reserved. P/N 46092 Rev.2